Telomir Pharmaceuticals

Historical price data

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

Telomir-1 is an oral small molecule metal ion regulator designed to lengthen telomeres and chelate/excess iron and copper, targeting oxidative stress and cellular dysfunction at the root of aging and multiple chronic diseases.

Telomir operates in a nascent field with few direct competitors targeting telomere lengthening. However, in each specific disease indication, it will face intense competition from large pharma and biotech companies with approved drugs and advanced pipelines (e.g., GLP-1 agonists in diabetes, anti-amyloids in Alzheimer's). Its differentiation hinges on proving its novel, root-cause, oral approach provides superior or complementary benefits to existing standards of care.